NR2F6 is more highly expressed in breast cancer than in normal breast tissue; NR profiling with the NCI-60 cancer cell panel indicates that cells with lower NR2F6 expression exhibit higher sensitivity to anti-cancer drugs targeting microtubules [12,18]. This evidence concerns the gene NR2F6 and breast carcinoma.